IDEAYA Biosciences, Inc. (IDYA) stock
IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/303% above fair value
$27.40−2.96 (-9.75%)
Close on Nov 17, 2026Market cap $2.64BP/E –Yield –
IDEAYA Biosciences cash
Cash and short-term investments held at the end of each period.
IDEAYA Biosciences's cash was $828.96M at Jun 30, 2026. For fiscal 2025 it was $639.39M, down 5.6% from the year before. The highest annual figure on record is $677.12M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $639.39M | -5.6% |
| FY2024 | Dec 31, 2024 | $677.12M | +28.9% |
| FY2023 | Dec 31, 2023 | $525.11M | +43.9% |
| FY2022 | Dec 31, 2022 | $364.94M | +47.8% |
| FY2021 | Dec 31, 2021 | $246.88M | -13.0% |
| FY2020 | Dec 31, 2020 | $283.69M | +186.4% |
| FY2019 | Dec 31, 2019 | $99.06M | +10.0% |
| FY2018 | Dec 31, 2018 | $90.07M | +1393.2% |
| FY2017 | Dec 31, 2017 | $6.03M | -37.8% |
| FY2016 | Dec 31, 2016 | $9.69M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $828.96M | +23.8% |
| Q1 FY2026 | Mar 31, 2026 | $671.20M | -3.1% |
| Q4 FY2025 | Dec 31, 2025 | $639.39M | -5.6% |
| Q3 FY2025 | Sep 30, 2025 | $786.89M | -14.5% |
| Q2 FY2025 | Jun 30, 2025 | $669.74M | -4.5% |
| Q1 FY2025 | Mar 31, 2025 | $692.51M | -0.9% |
| Q4 FY2024 | Dec 31, 2024 | $677.12M | +28.9% |
| Q3 FY2024 | Sep 30, 2024 | $920.03M | +96.3% |
| Q2 FY2024 | Jun 30, 2024 | $701.66M | +42.1% |
| Q1 FY2024 | Mar 31, 2024 | $698.77M | +105.8% |
| Q4 FY2023 | Dec 31, 2023 | $525.11M | +43.9% |
| Q3 FY2023 | Sep 30, 2023 | $468.75M | +21.4% |
| Q2 FY2023 | Jun 30, 2023 | $493.72M | +83.8% |
| Q1 FY2023 | Mar 31, 2023 | $339.47M | +34.4% |
| Q4 FY2022 | Dec 31, 2022 | $364.94M | +47.8% |
| Q3 FY2022 | Sep 30, 2022 | $386.24M | +46.0% |
| Q2 FY2022 | Jun 30, 2022 | $268.62M | -2.0% |
| Q1 FY2022 | Mar 31, 2022 | $252.60M | -16.4% |
| Q4 FY2021 | Dec 31, 2021 | $246.88M | -13.0% |
| Q3 FY2021 | Sep 30, 2021 | $264.55M | -5.1% |
| Q2 FY2021 | Jun 30, 2021 | $274.18M | +60.9% |
| Q1 FY2021 | Mar 31, 2021 | $302.32M | +244.1% |
| Q4 FY2020 | Dec 31, 2020 | $283.69M | +186.4% |
| Q3 FY2020 | Sep 30, 2020 | $278.68M | +154.7% |
| Q2 FY2020 | Jun 30, 2020 | $170.41M | +41.8% |
| Q1 FY2020 | Mar 31, 2020 | $87.86M | +148.9% |
| Q4 FY2019 | Dec 31, 2019 | $99.06M | +10.0% |
| Q3 FY2019 | Sep 30, 2019 | $109.40M | +409.2% |
| Q2 FY2019 | Jun 30, 2019 | $120.20M | +383.3% |
| Q1 FY2019 | Mar 31, 2019 | $35.30M | +485.2% |
| Q4 FY2018 | Dec 31, 2018 | $90.07M | +829.2% |
| Q3 FY2018 | Sep 30, 2018 | $21.48M | – |
| Q2 FY2018 | Jun 30, 2018 | $24.87M | – |
| Q4 FY2017 | Dec 31, 2017 | $6.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.69M | – |
See a number that looks wrong?